Designing a First-in-Human Dose-Escalation Study of an Oral RAS(ON) Multi-Selective Inhibitor in Advanced RAS-Mutant Solid Tumors: Scientific and Regulatory Justification and Phase 1 Protocol Synopsis

The first human dose of an oncology drug must be chosen with less information than any later dose, and the design that surrounds it has to protect patients who cannot be offered the safety margin a healthy volunteer would receive. This article develops the scientific and regulatory justification for a hypothetical first-in-human study of an oral RAS(ON) multi-selective inhibitor, a small molecule that forms a tri-complex with an intracellular chaperone and active, GTP-bound RAS, in adults with advanced RAS-mutant solid tumors. It derives a 10 mg starting dose from assumed ICH S9 toxicology benchmarks, specifies eight dose levels from 10 to 400 mg once daily under a traditional 3+3 design with a single-dose pharmacokinetic run-in, and presents a complete protocol synopsis: objectives, eligibility, dose-limiting toxicity rules, a schedule of events, safety monitoring, and statistics for up to 48 participants. The article also corrects a design inconsistency common in student protocols, in which single- and multiple-ascending-dose labels are applied to an oncology study that has neither, and closes with recommendations for first-in-human oncology design.Keywords: first-in-human; RAS(ON) inhibitor; ICH S9; dose escalation; 3+3 design; starting dose; Phase 1 protocol; IND

Authors

Institutions

Publication Details

Journal
Zenodo (CERN European Organization for Nuclear Research)
Published
2026-11-21
DOI
https://doi.org/10.5281/zenodo.24426098
Primary Topic
Statistical Methods in Clinical Trials
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Designing a First-in-Human Dose-Escalation Study of an Oral RAS(ON) Multi-Selective Inhibitor in Advanced RAS-Mutant Solid Tumors: Scientific and Regulatory Justification and Phase 1 Protocol Synopsis

Avinash Dundigalla, Peivand Pirouzi, Daxaben Jigneshkumar Patel, Afeefa Mahmood et al.
Zenodo (CERN European Organization for Nuclear Research)
Statistical Methods in Clinical Trials
article

Designing a First-in-Human Dose-Escalation Study of an Oral RAS(ON) Multi-Selective Inhibitor in Advanced RAS-Mutant Solid Tumors: Scientific and Regulatory Justification and Phase 1 Protocol Synopsis

Avinash Dundigalla, Peivand Pirouzi, Daxaben Jigneshkumar Patel, Afeefa Mahmood, Kritica
article en

Abstract

The first human dose of an oncology drug must be chosen with less information than any later dose, and the design that surrounds it has to protect patients who cannot be offered the safety margin a healthy volunteer would receive. This article develops the scientific and regulatory justification for a hypothetical first-in-human study of an oral RAS(ON) multi-selective inhibitor, a small molecule that forms a tri-complex with an intracellular chaperone and active, GTP-bound RAS, in adults with advanced RAS-mutant solid tumors. It derives a 10 mg starting dose from assumed ICH S9 toxicology benchmarks, specifies eight dose levels from 10 to 400 mg once daily under a traditional 3+3 design with a single-dose pharmacokinetic run-in, and presents a complete protocol synopsis: objectives, eligibility, dose-limiting toxicity rules, a schedule of events, safety monitoring, and statistics for up to 48 participants. The article also corrects a design inconsistency common in student protocols, in which single- and multiple-ascending-dose labels are applied to an oncology study that has neither, and closes with recommendations for first-in-human oncology design.Keywords: first-in-human; RAS(ON) inhibitor; ICH S9; dose escalation; 3+3 design; starting dose; Phase 1 protocol; IND

Zenodo (CERN European Organization for Nuclear Research)
Northeastern University (US)
Statistical Methods in Clinical Trials
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon